Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti's Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026. The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and you don'

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. Our focus is sharper than ever — and the progress we are making reflects that. Below is a full account of what has been

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB:SIGY) ("Sigyn"), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spe

SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now actively enrolling participants in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). To date, four patients have been enrolled and dosed at Mackay Base Hospital in Queensland, Australia, the first site activated in the trial. Concussion and mild traumatic brain injury represent the most prominent neurological condition without an FDA-a

• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that 2 patients and 8 study drug doses have been administered in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of mild traumatic brain injury (mTBI) a.k.a., concussion. Enrollment is progressing at Mackay Base Hospital in Queensland, Australia, the first activated site in the trial, with addition

Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company's lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The milestone was achieved at Mackay Hospital in Australia — the first sit

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 to the Company's

REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The Annual Report on Form 10-K, including audited financial statements fo

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial operations at the first of three planned trial sites in Australia, including completion of site staff training, protocol orientation, and site regulatory documentation. The remaining two clinical trial sites are currently completing their Research Govern

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform. The Company's portfolio expansion initiative is being pursued independently of its existing partnership with Recepto

4/A - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

3 - ORAGENICS INC (0001174940) (Issuer)

4 - ORAGENICS INC (0001174940) (Issuer)

DEFA14A - ORAGENICS INC (0001174940) (Filer)

DEF 14A - ORAGENICS INC (0001174940) (Filer)

8-K - ORAGENICS INC (0001174940) (Filer)

PRE 14A - ORAGENICS INC (0001174940) (Filer)

10-Q - ORAGENICS INC (0001174940) (Filer)

8-K - ORAGENICS INC (0001174940) (Filer)

8-K - ORAGENICS INC (0001174940) (Filer)

8-K - ORAGENICS INC (0001174940) (Filer)

EFFECT - ORAGENICS INC (0001174940) (Filer)

S-3/A - ORAGENICS INC (0001174940) (Filer)

Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

SC 13G/A - ORAGENICS INC (0001174940) (Subject)

SC 13G/A - ORAGENICS INC (0001174940) (Subject)

SC 13G - ORAGENICS INC (0001174940) (Subject)

SC 13G - ORAGENICS INC (0001174940) (Subject)

SC 13D - ORAGENICS INC (0001174940) (Subject)

SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics' lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 is a new chemical entity (NCE) designed to target the brain through delivery into the nasal cavity and onward to the brain. A 40-patient Phase I study was completed and showed the drug to be safe and well-tolerated. In the recent past, Dr.

Oragenics, Inc. (NYSE:OGEN) (the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company's Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the "Separation Agreement"), pursuant to which Ms. Murphy's employment with the Company terminated effective February 12, 2024. Ms. Murphy will, however, continue to serve the Company as a member of the Company's board of directors (the "Board"). The Separation Agreement provides Ms. Murphy with the benefits under her employment agreement with the Company

Adds Clinical-Stage Product Pipeline, Expands Intranasal Drug Delivery Technologies, Names Michael Redmond as President of Oragenics Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.'s (OTCQB:ODYY) ("Odyssey") proprietary neurological drug therapies and technologies. The acquired assets include ONP-002 and a unique nasal delivery device, Odyssey's lead concussion asset, believed to be a first-in-class intranasal drug under development for the treatment of moderate-to-severe concussion in the acute through subacute phases. In preclinical animal studies, the asset demonstra

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. "We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board," said Charlie Pope, Chairman of Oragenics. "Bruce's deep experience in high-technology global businesses will be invaluable to Oragenics as we grow our portfolio. John's proven leadership in the life sciences, capital raising and financial management will be critical to our future. We are confident that Bruce and John will provide valuable perspectives as we continue to execute our strategy, pursue our mission to serve patients and en

Gains Nasal Delivery Technologies and Expands Product Pipeline Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey's assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as Odyssey's proprietary powder formulation and its nasal delivery device. Odyssey will retain its other assets and operations. The asset purchase includes cash payments to Odyssey

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies. "Janet's extensive professional background as a public company CFO will be important to Oragenics as we drive forward with our development plans. She brings particularly valuable expertise in raising capital and M&A transactions to deliver strong strategic results. We expect that her experience in thes

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011. Dr. Telling will remain on the Board as an independent director and as a member of both the audit and nominating and corporate governance committees. Dr. Telling stated: "It has been an honor and privilege to serve as Chairman of Oragenics for over a decade and I look forward to assisting with the Company's